Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Celcuity 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
3.19B
Market cap3.19B
Price-Earnings ratio
-15.25
Price-Earnings ratio-15.25
Dividend yield
—
Dividend yield—
Average volume
2.13M
Average volume2.13M
High today
$66.29
High today$66.29
Low today
$63.49
Low today$63.49
Open price
$65.57
Open price$65.57
Volume
1.25M
Volume1.25M
52 Week high
$151.02
52 Week high$151.02
52 Week low
$53.54
52 Week low$53.54

Stock Snapshot

As of today, Celcuity(CELC) shares are valued at $65.25. The company's market cap stands at 3.19B, with a P/E ratio of -15.25.

On 2026-10-23, Celcuity(CELC) stock moved within a range of $63.49 to $66.29. With shares now at $65.25, the stock is trading +2.8% above its intraday low and -1.6% below the session's peak.

Trading volume for Celcuity(CELC) stock has reached 1.25M, versus its average volume of 2.13M.

The stock's 52-week range extends from a low of $53.54 to a high of $151.02.

The stock's 52-week range extends from a low of $53.54 to a high of $151.02.

CELC News

TipRanks 10h
Celcuity announces updated results from gedatolisib trial at ESMO

Celcuity (CELC) announced updated clinical results from the Phase 1b/2 study evaluating gedatolisib in patients with metastatic castration-resistant prostate ca...

Investing.com 1d
Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity - Investing.com

...

Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity - Investing.com
TipRanks 2d
Celcuity initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Li Watsek initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target Published first on TheFly – the ultim...

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.